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A B S T R A C T
The synthesis of hydrophilic graphene-based yolk-shell magnetic nanoparticles functionalized with copolymer
pluronic F-127 (GYSMNP@PF127) is herein reported to achieve an efficient multifunctional biomedical system
for mild hyperthermia and stimuli-responsive drug delivery. In vitro tests revealed the extraordinary ability of
GYSMNP@PF127 to act as smart stimuli-responsive multifunctional nanomedicine platform for cancer therapy,
exhibiting (i) an outstanding loading capacity of 91% (w/w, representing 910 μgmg−1) of the chemotherapeutic
drug doxorubicin, (ii) a high heating efficiency under an alternating (AC) magnetic field (intrinsic power loss
ranging from 2.1–2.7 nHm2 kg−1), and (iii) a dual pH and thermal stimuli-responsive drug controlled release
(46% at acidic tumour pH vs 7% at physiological pH) under AC magnetic field, in just 30min. Additionally,
GYSMNP@PF127 presents optimal hydrodynamic diameter (DH=180 nm) with negative surface charge, high
haemocompatibility for blood stream applications and tumour cellular uptake of drug nanocarriers. Due to its
physicochemical, magnetic and biocompatibility properties, the developed graphene-based magnetic nano-
carrier shows high promise as dual exogenous (AC field)/endogenous (pH) stimuli-responsive actuators for
targeted thermo-chemotherapy, combining magnetic hyperthermia and controlled drug release triggered by the
abnormal tumour environment. The presented strategy and findings can represent a new way to design and
develop highly stable added-value graphene-based nanostructures for the combined treatment of cancer.
1. Introduction
Cancer incidence and mortality are growing worldwide at an
alarming pace, emphasizing the urgent need for new strategies to
combat this disease [1]. The frontiers of cancer research are currently
focused on the design of multifunctional magnetic nanoparticles cap-
able to achieve the synergistic cancer theranostics, by combining the
heat effect induced by hyperthermia, the unique drug delivery prop-
erties and the improved ability of magnetic nanoparticles to accelerate
the MRI relaxation process as T2 contrast agent [2–4]. For this purpose,
many magnetic nanoparticle-based drug delivery systems have been
developed in the last decade [5–9]. However, the major bottleneck for
their clinical theranostic achievement has been the low drug loading
capacity and poor controlled-drug release of the developed magnetic
nanoparticles [9,10], as well as the lack of targeted drug delivery at the
tumour site.
Graphene-based magnetic nanoparticles, due to their unique prop-
erties, such as high chemical and thermal stability, high charge carrier
mobility and large surface area for functionalization [10,11], have the
potentiality to be designed as efficient multifunctional nanocarrier
systems with enhanced capability to protect the magnetic core from
oxidation or dissolution in acidic environment [2,12]. Moreover, its
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unique sp2 carbon structure with π-π stacking and negative surface
charge, enables the adsorption of a variety of molecules, e.g. che-
motherapeutic drugs, DNA and/or RNA, which can be specifically ac-
cumulated into tumours, either by active targeting or by the enhanced
permeability and retention effect [2,13]. In addition, this non-covalent
interaction mechanism allows the use of graphene-based magnetic na-
noparticles as pH stimuli-responsive controlled drug release systems,
triggered by the abnormal acidic pH values (around 4.5–5.5) that are
found in tumour endosome/lysosome microenvironments [14]. On the
other hand, the superparamagnetic core of these nanocomposites allows
heat generation in the tumour under an AC magnetic field (AMF) that
induces cancer cells death, by the so-called magnetic hyperthermia, and
can simultaneously boost the drug release on those abnormal tissues. In
fact, the combination of magnetic hyperthermia and chemotherapy has
been demonstrated in clinical trials to have a synergistic effect on the
cancer therapy response compared to the therapeutic effect achieved
when these treatment procedures are applied alone [15]. In this regard,
graphene-based magnetic nanomaterials, developed as multifunctional
nanocarriers, are able to have a dramatic impact in medicine and in the
treatment of cancer. However, the majority of the magnetic drug na-
nocarriers reported in the literature revealed a low saturation magne-
tization (Ms) profile [2,11,13,16,17], limiting the utility of these mag-
netic nanocomposites for magnetic hyperthermia. Also the possible
aggregation and precipitation of graphene-based materials in the pre-
sence of electrolyte solutions, such as the body fluids [18], is an issue
that needs to be addressed.
To overcome these drawbacks, a simple protocol is herein reported
to synthesize a material consisting of hydrophilic graphene-based yolk-
shell magnetic nanoparticles (GYSMNP) functionalized with copolymer
pluronic F-127 (GYSMNP@PF127). Pluronic copolymers have been
investigated for the development of thermo-responsive hydrogels and
drug delivery systems [19]. Particularly, pluronic F-127, with non-
proprietary name poloxamer 407, is a water-soluble and biocompatible
triblock copolymer – containing hydrophilic poly(ethylene oxide)
(PEO) blocks and hydrophobic poly(propylene oxide) (PPO) blocks
arranged as PEO-PPO-PEO, and it is approved by the U.S. Food and
Drug Administration (FDA) for use as food additive and in pharma-
ceutical formulations [20]. The functionalization of nanoparticles with
pluronic F-127 allows the incorporation of a hydrophilic PEO corona
that reduces the aggregation of nanoparticles and the adsorption of
blood proteins, as well as increases the biocompatibility of the nano-
systems and its colloidal stability, which prolongs blood circulation
[19,21]. Additionally, the terminal hydroxyl functional groups allow
the conjugation with selected ligands for the development of multi-
functional nanosystems with high potential for active tumour targeting
and therapeutic efficiency enhancement [21]. In this study, GYSMNP@
PF127 was conjugated with doxorubicin (DOX), a highly potent che-
motherapeutic drug clinically used against a broad spectrum of cancers.
The developed therapeutic nanosystem was thoroughly characterized
and investigated as multifunctional nanocarrier to combine magnetic




Ammonium hydroxide solution, NH4OH (25 wt% in H2O), was
purchased from Merck (NJ, USA). Iron (II) chloride tetrahydrate,
FeCl2.4H2O (99 wt%), ethanol absolute, C2H6O (99.8%), nitric acid,
HNO3 (70 wt%), copolymer pluronic F-127, PEO106PPO70PEO106
(Mw=12,600), sodium chloride, NaCl (99.5 wt%), sodium phosphate
monobasic, NaH2PO4 (99.0 wt%), potassium chloride, KCl (99 wt%),
sodium phosphate dibasic, Na2HPO4 (99.0 wt%) and sodium hydroxide,
NaOH (98 wt%), were obtained from Sigma-Aldrich (MO, USA). Iron
(III) chloride hexahydrate, FeCl3.6H2O (97%), and formaldehyde (37 wt
% stabilized with methanol) were supplied by Panreac (Barcelona,
Spain). Resorcinol (98 wt%) was supplied by Fisher chemicals (MA,
USA). Tetraethyl orthosilicate, TEOS (98 wt%), was obtained from
Fluka (MO, USA). Doxorubicin hydrochloride, DOX (98 wt%), was
purchased from Discovery Fine Chemicals (Wimborne, UK).
Physiological salt solution (PSS) with 0.9% NaCl was supplied by B.
Braun Medical (Germany). Hoechst dye (BisBenzimide) and monoclonal
anti-α-tubulin antibody produced in mouse (B512) was obtained from
Sigma-Aldrich (Sant Louis, MO, USA). Goat anti-Mouse IgG (H+L)
Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 was ob-
tained from Invitrogen (USA). The cell line HepG2 was purchased from
Deutshe Sammlung von Mikroorganismen and Zellkulturen Gmbit
(DSMZ). RPMI 1640 medium, hank's balanced salt solution (HBSS),
fetal bovine serum (FBS), L-glutamine, trypsin-EDTA, penicillin/strep-
tomycin solution (100 UmL−1 and 100mgmL−1, respectively) were
purchased from Gibco Invitrogen Life Technologies (Carlsbad, CA,
USA). All chemicals were used as received, without further purification.
All aqueous solutions were prepared using ultrapure water
(18.2 MΩ cm at 25 °C), produced in a Milli-Q system (Millipore), or
deionized water.
2.2. Synthesis of GYSMNP
The GYSMNP material was synthesized in two main steps: (i)
synthesis of the superparamagnetic core, and (ii) formation of the
graphene-based shell architecture.
In the first step, the superparamagnetic magnetite (Fe3O4) core with
mean diameter of 18 nm was synthesized through co-precipitation of
Fe2+ and Fe3+ (with a molar ratio of 1:2) in a basic solution of am-
monium hydroxide, at 55 °C, adapting the procedure described else-
where [22]. Afterwards, in the second step, the graphene-based yolk-
shell architecture was achieved via one-pot strategy of hydrolysis and
polymerisation of the precursors resorcinol, formaldehyde and TEOS,
by adapting and optimizing the procedure described elsewhere [23]. In
brief, an ultra-sonicated mixture of 0.25 g magnetite with 150mL of
ethanol and 50mL of deionized water, was transferred into a 250mL
two-necked round-bottom flask. After reaching 30 °C, 0.10 g of re-
sorcinol and 1.4 mL of ammonium hydroxide were added to the mixture
that was magnetically stirred for 1 h. After that, 0.15mL of for-
maldehyde solution and 0.21mL of TEOS were added dropwise and
maintained under stirring at 30 °C for 6 h. The mixture was then heated
at 80 °C for another 8 h under constant stirring. The resulting magnetic
product was washed by centrifugation several times with deionized
water and absolute ethanol, and dried overnight at 60 °C. The obtained
samples were sequentially annealed under a N2 flow (100 cm3min−1)
in a tubular vertical oven at 120 and 400 °C during 60min at each
temperature, and then at 600 °C for 240min, defining a heating ramp of
2 °Cmin−1. Lastly, silica (positioned between the magnetic core and the
outer shell) was removed by an etching process in a strong basic solu-
tion of sodium hydroxide (10mol L−1, 16 h at room temperature with
stirring). The samples were washed by centrifugation several times with
deionized water and absolute ethanol, and dried overnight at 60 °C,
resulting in the graphene-based yolk-shell magnetic nanoparticles
(GYSMNP).
2.3. Hydrophilization of GYSMNP
The colloidal stabilization of GYSMNP was performed by chemical
functionalization of the graphene-based shell. For this purpose, an acid
treatment at mild conditions was performed to incorporate carboxylic
and hydroxyl groups, without compromising the magnetic core, and
followed by functionalization of the copolymer pluronic F-127 (PF127)
onto the surface of GYSMNP. PF127 was used as enhancer for both
colloidal stabilization and biocompatibility of GYSMNP [24]. Briefly,
the initial surface functionalization of GYSMNP was conducted in a
250mL round-bottom flask at 65 °C under vigorous magnetic stirring
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(C-Mag HS7, IKA). The as-synthetized GYSMNP material (5 mgmL−1)
was oxidized with HNO3 (1mol L−1) during 3 h, washed and dried
overnight at 60 °C. Once the surface activated, GYSMNP (2mgmL−1)
was functionalized with PF127 (40mgmL−1) for 5 h in magnetic stir-
ring, at room temperature. The resulting solution was washed by cen-
trifugation (13,000 rpm, 20min) with deionized water to remove un-
bounded copolymer, and the final GYSMNP@PF127 pellet redispersed
in a phosphate buffer solution or deionized water at desired con-
centration. The obtained hydrophilic GYSMNP@PF127 material was
further used to encapsulate the chemotherapeutic drug doxorubicin
(DOX).
2.4. Characterization of GYSMNP
The phase formation and crystallographic state of the synthesized
materials were investigated in an Expert Pro Philips X-ray dif-
fractometer. Wide angle powder X-ray diffraction (XRD) analysis was
carried out using a CuKα radiation (λ=1.54°).
The Raman spectra of the samples were recorded at ambient tem-
perature with a 20× objective, using a micro-Raman spectrometer
apparatus (Micro-Raman DXR, Thermo scientific) with a 532 nm laser
excitation. Curve fitting for the Raman data was carried with Origin 8.0
software using the Lorentz function.
The morphology and microstructure of the materials were evaluated
using a probe Cs corrected High-Resolution Scanning Transmission
Electron Microscope (HR-STEM), model Jeol ARM 200 CF.
The amount of carbon and magnetic core of the as-synthetized
GYSMNP material was determined by thermogravimetric (TG) analysis
(STA 449C Jupiter, Netzsch), heating the samples in air flow from 50 to
950 °C, at 20 °Cmin−1. The organic content of functionalized
GYSMNP@PF127 was determined in TG analysis under N2 atmosphere
by heating the samples from 50 to 550 °C at a rate of 10 °Cmin−1, and
comparing the results with those obtained with the as-synthetized
GYSMNP, analysed under the same conditions and used as reference.
The textural properties of GYSMNP were studied using N2 adsorp-
tion-desorption isotherms obtained at ˗ 196 °C in a Quantachrome
NOVA 4200e adsorption analyser. The specific surface area (SBET) was
calculated by applying the Brunauer-Emmett-Teller (BET) equation
[25]; the micropore volume (Vmicro) and the non-microporous surface
area (Smeso) were determined by the t-method using a standard isotherm
[26]; and the total pore volume (Vtotal) was derived from the amount of
N2 adsorbed at a relative pressure close to unity (P/P0= 0.995).
The average hydrodynamic diameter and surface charge of
GYSMNP@PF127 were determined by dynamic light scattering (DLS)
and zeta potential (ZP) measurements (Zetasizer Nano, Malvern
Instruments) at a concentration of 0.1 mgmL−1 dispersed in Milli-Q
water at room temperature (n=3).
The pH at the point of zero charge (pHPZC) of the nanomaterials was
determined adapting the methodology described elsewhere [27].
Briefly, solutions with varying initial pH (2−12) were prepared using
HCl (1.0 mol L−1) or NaOH (1.0mol L−1) and 20mL of NaCl
(0.01 mol L−1) as electrolyte. Each solution was incubated with 0.05 g
of the material and the final pH was measured after 48 h of continuous
stirring at room temperature. The pHPZC was determined by inter-
cepting the obtained final pH vs. initial pH curve with the straight line
final pH= initial pH.
The Fourier transform infrared (FTIR) spectroscopy was performed
with a Perkin Elmer Spectrum equipment using KBr pellets.
The magnetic properties of the superparamagnetic core (Fe3O4) and
graphene-based nanocarriers, were investigated with a superconducting
quantum interference device (SQUID-VSM) magnetometer from
Quantum Design. Hysteresis curves at room temperature were recorded
at magnetic fields between −20 kOe and 20 kOe.
2.5. Drug loading studies
The drug loading experiments were carried out by mixing a given
amount of DOX (from 50 to 500 μgmL−1) and a fixed amount of
GYSMNP@PF127 (500 μgmL−1) in a phosphate buffer solution with
pH 7.4. The suspensions were kept in a shaking incubator at room
temperature during 48 h in darkness, and the loading tests were per-
formed in triplicate. At the end of each experiment, the GYSMNP@
PF127 material loaded with the drug (referred as GYSMNP@PF127-
DOX) was collected by centrifugation at 15000 rpm for 30min. The
supernatant (containing the free drug) was used to monitor the absor-
bance at 480 nm (characteristic of DOX), and determine the drug con-
centration. The drug loading efficiency and drug loading capacity were
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2.6. pH and temperature-dependent drug release
The pH and temperature dependent drug release of DOX loaded on
GYSMNP@PF127 were evaluated in the absence of AMF (AC magnetic
field). For this purpose, freeze-dried GYSMNP@PF127-DOX samples
(2.0 mg) suspended in phosphate buffer solution (20mL) at physiolo-
gical (pH 7.4) and acidic pH levels (pH 6.0 and 4.5), were incubated at
37 °C (physiological body temperature) and 45 °C (hyperthermia tem-
perature). At selected time intervals (0.5, 1, 2, 3, 4, 6, 8, 24 and 48 h),
samples were collected, centrifuged, and the supernatant used to
monitor the absorbance at 480 nm to determine the pH and tempera-
ture-dependent release of DOX.
2.7. DOX release kinetics analysis
Drug release data were fitted to first-order (release dependent of
concentration), Higuchi (release by diffusion) and Korsmeyer-Peppas
(log (cumulative drug release) vs log (time)) models in order to un-
derstand the drug release kinetics. The kinetic model that best fitted the
drug release data was selected by comparing the respective regression
coefficients (R2) of the different models. The Korsmeyer-Peppas model
is used to characterize different release mechanisms from polymeric
systems by using the n (release exponent) value. For cylindrical shaped
matrices, values of n < 0.45 means quasi-Fickian diffusion, n=0.45
means Fickian diffusion, 0.45 < n < 0.89 means anomalous diffusion
(diffusion+ erosion), n=0.89 means non-Fickian case II (zero order)
and n > 0.89 means non-Fickian supercase II [28].
2.8. Validation of GYSMNP@PF127-DOX as dual pH- and AMF/
temperature-responsive drug nanocarrier
GYSMNP@PF127 heating efficiencies were first evaluated in a hy-
perthermia equipment (Fives Celes, France) under an oscillating mag-
netic field of H=21.0 kAm−1 and 340 kHz. For this purpose, 0.3 mg of
GYSMNP@PF127 was dispersed in water at a concentration of
1.5 mgmL−1 and placed in the mid-point of a cupper coil. Then, the
temperature increase was logged as a function of time during the ex-
ternal AMF application using an optical fibre probe centred in the na-
noparticle dispersion. The heating measurements started at stabilized
room temperature and were limited to 10min. The specific absorption
rate (SAR, W g Fe−1) was calculated according to Eq. (3) [29]:











where C is the specific heat capacity of the medium, m water and m Fe are
the mass of water and iron in the dispersion, respectively, and ΔT/Δt is
the initial temperature rise rate. In addition, the intrinsic power loss
(IPL, nHm2 kg−1), which is independent of the magnetic field para-
meters and allows direct comparison between different experiments,
was calculated using Eq. (4) [30]:
=IPL SAR
H f2 (4)
where SAR is given by Eq. (3), H is the field amplitude and f the fre-
quency used in the hyperthermia experimental setup.
On another set of experiments, the dual pH and AMF/temperature-
responsive drug release of GYSMNP@PF127-DOX were determined
under the same AMF conditions (H=21.0 kAm−1 and f=340 kHz) at
a concentration of 3.0mgmL−1. For this purpose, freeze-dried
GYSMNP@PF127-DOX was dispersed in 0.3mL of phosphate buffer at
pH 7.4 or 4.5, and maintained under AMF for 30min. After that, the
supernatant was centrifuged and used to monitor the absorbance at
480 nm to determine the pH- and AMF/temperature-dependent release
of DOX under magnetic hyperthermia.
2.9. In vitro cell tests
2.9.1. Haemocompatibility tests
The blood-nanocarriers biocompatibility was tested by haemolysis
assay according to previous reports [22,31]. Briefly, human whole
blood from healthy donors was collected into 2.7 mL tubes (S-Monov-
ette, Sarstedt) containing ethylenediaminetetraacetic acid (EDTA). The
whole blood was diluted in a ratio 1:2 (v/v) in PSS (physiological salt
solution) and centrifuged twice at 2500 rpm for 10min to isolate the
red blood cells (RBCs). The isolated RBCs were diluted in 15mL of PSS.
0.4 mL of diluted RBCs suspension was exposed to 1.6mL of GYSMNP@
PF127 at different concentrations (10, 50, 100, 200, 400, 500 μgmL−1).
Positive control was obtained using the 0.4 mL of RBCs diluted 1.6 mL
of PSS buffer and the negative control by adding to the diluted whole
blood, deionized water in the same volume of (1:1, v/v). Samples were
incubated on an orbital shaker at 37 °C during 3 h. The released hae-
moglobin was determined after centrifugation at 2500 rpm for 10min,
followed by photometric analysis of the supernatant at 570 nm. The
haemolysis ratio (HR) in percentage was calculated from the optical
(OD) density using Eq. (5) [22], from two independent experiments in
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2.9.2. Cell culture
Two cell lines were used for the cytotoxicity assays, namely porcine
liver primary cells (PLP2), established by some of the authors [32], and
a human liver cancer cell line (HepG2). HepG2 was used for cellular
uptake of drug nanocarriers. Prior to the in vitro cell studies, both cell
lines were cultured in RPMI-1640 medium containing 10% foetal bo-
vine serum (FBS), 1% of glutaraldehyde, 1% of penicillin and 1% of
streptomycin, under a humid atmosphere containing 5% of CO2, at
37 °C. The culture medium was replaced every two days, after the
evaluation of the normal cell growth and morphology.
2.9.3. Cell cytotoxicity assays and cellular uptake of drug nanocarriers
The cytotoxicity of GYSMNP@PF127 and GYSMNP@PF127-DOX
was assessed in PLP2 and HepG2, respectively, using the sulfurhoda-
mine B (SRB) colorimetric assay as described elsewhere [33]. SRB assay
has been widely used for drug-toxicity testing in different types of
cancerous and non-cancerous cell lines [34]. Practical advances makes
the SRB assay very sensitive to measure drug-induced cytotoxicity and
cell proliferation even at large-scale drug-screening applications [35].
Briefly, 100 μL of RPMI-1640 complete medium containing different
concentrations of GYSMNP@PF127 or GYSMNP@PF127-DOX, ranging
from 0.05 μgmL−1 to 50 μgmL−1, were seeded in 96-well plates. Im-
mediately after, 100 μL of RPMI-1640 complete medium containing the
respective cell lines in test were added to each well, at an initial cell
density of 1.0× 104. In addition, control wells containing just cells
with cultured medium were seeded and used as blank and control. All
the assays were performed in two individual tissue-culture plates in
duplicated wells (n=4) and cultured in 5% CO2, at 37 °C for 48 h. The
percent cell viability was calculated considering the untreated cells as
100% viability. The results were used to determine the GI50, as the
concentration that inhibits the growth of cells by 50%.
Moreover, HepG2 cell line was incubated with 5 μgmL−1 of
GYSMNP@PF127-DOX during 2, 4 and 6 h. Cells were fixed in 4%
paraformaldehyde. Hoechst dye was used to stain DNA. Microtubules
were immunolabeled with the monoclonal anti-tubulin antibody (B512)
that was recognized by a secondary goat anti-mouse immunoglobulin G
(IgG) conjugated Alexa Fluor 488. Confocal microscopy images were
obtained with a Carl Zeiss inverted microscope attached to the LSM 780
confocal system (software; ZEN 2010).
3. Results and discussion
3.1. Synthesis and characterization of GYSMNP@PF127
Fig. 1 illustrates the protocol of synthesis that was implemented in
this study.
HR-TEM images of GYSMNP@PF127, Fig. 2(a) and (b), confirmed
the formation of the yolk-shell magnetic nanostructure, namely a small
cluster of magnetite cores covered by a graphene-based shell. TEM
image at low magnification of the GYSMNP nanostructures is shown in
Fig. S1, ESI. The average hydrodynamic dimension (DH) of GYSMNP@
PF127 was found to be 180 nm (Fig. 2(b)), with polydispersion index
(PDI) of 0.14 (Table 1). Due to the enhanced permeability and retention
(EPR) effect, nanoparticles with size range between 10 and 200 nm are
ascribed to be preferentially accumulated into tumour rather than in
healthy tissues [15]. Additionally, particles in the range of 100–200 nm
are large enough to avoid uptake by the liver and splenic filtration [36].
Thus, the DH of GYSMNP@PF127 shows an optimal dimension for
suitable intravenous administration and EPR effect with prolonged
blood circulation.
Additionally, the zeta potential of GYSMNP, before and after func-
tionalization with nitric acid and pluronic F-127 (PF127), was de-
termined. A higher negative value, around ˗ 37mV, was determined for
the functionalized samples with respect to as-synthetized GYSMNP,
with zeta potential around ˗ 17mV (data not shown). These results
indicate the incorporation of carboxylic acid groups and negative
charged PF127 on the surface of GYSMNP, with a consequent increase
in the colloidal stability. Moreover, negative surface charge is ascribed
to increased nanoparticle circulation by avoiding opsonisation phe-
nomenon and their elimination from blood by macrophage cells [37].
Fig. 3 (a) shows the wide angle powder XRD patterns for both as-
synthesized Fe3O4 cores and GYSMNP. The peaks at 2θ, corresponding
to (111), (220), (311), (222), (400), (422), (511) and (440), are as-
signed to the characteristic diffraction peaks of Fe3O4 nanoparticles
(JCPDS no. 19-629). GYSMNP showed additional peaks, namely (110)
and (211), assigned to a tiny amount of secondary metal iron phase,
possibly due to the reduction of magnetite during the thermal annealing
procedure (600 °C) in N2 atmosphere. A peak (002) at 24.3° was also
detected and assigned to the presence of the graphene-based material
[38].
Results from thermogravimetric (TG) analysis under air atmosphere
are shown in Fig. 3(b). The first significant weight loss below 175 °C can
be attributed to the evaporation of water molecules at the surface of the
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as-synthetized GYSMNP material. Above 200 °C, the weight loss can be
ascribed to the desorption of oxygen functional groups in the graphene-
based shells, at such temperatures typically assigned to epoxy, hydroxyl
and acidic carboxylic groups [39]. The sharp mass loss observed around
400 to 600 °C corresponds to the combustion of the carbon material,
suggesting a mass percentage of the graphene-based shells of 9.7%.
Thus, the mass percentage of magnetic core was calculated to be 88.0%.
Fig. 3(c) shows the Fourier transform infrared (FTIR) spectra of the
samples collected at different stages of the preparation process. All
samples show a FTIR spectrum with various oxygen-containing func-
tional groups in their structure including hydroxyl, namely CeOH
(3050–3800 cm−1 and 1070 cm−1), carboxyl (COOH,
1650–1750 cm−1), ketonic (C]O, 1600–1650 cm−1 and
1750–1850 cm−1) and epoxide (CeOeC, 1230–1320 cm−1) species, as
well as sp2-hybried C]C (1600–1680 cm−1) and alkanes (CeH,
1460 cm−1 and 1370–1385 cm−1), which are in accordance with pre-
vious reports for graphene oxide (GO) samples [40]. Moreover, a peak
at 570 cm−1, which is the characteristic peak of the stretching vibration
of FeeO bond from magnetite [41], was observed for all samples.
Particularly, an additional peak at 1106 cm−1 (CeO, 1085–1300 cm−1)
was verified for GYSMNP@PF127 (sample (iii) in Fig. 3(c)), as a result
of the incorporation of PF-127 onto its structure. The organic content of
the samples was determined by TG analysis under inert atmosphere,
ranging the temperature from 50 to 550 °C. Fig. 3(d) shows two sharp
weight losses for GYSMNP@PF127, the first weight loss occurring be-
tween 100 and 270 °C, which can be ascribed to the decomposition of
the surface oxygen groups, such as epoxy, hydroxyl and carboxylic
acids [42]. The second sharp weight loss occurs between 300 and
500 °C, which corresponds to the thermal decomposition of PF-127
[43], with a weight loss of 21%.
Fig. 3(e) shows the Raman spectra of GYSMNP. The presence of
graphene oxide is suggested by the D peak at 1350 cm−1, the conven-
tional G peak at 1582 cm−1 and the 2D peak at 2816 cm−1 [44]. To
better elucidate the type of graphene-based material, the three peaks
Fig. 1. Schematic representation of the steps involved in the development of the hydrophilic graphene-based yolk-shell magnetic nanoparticles (GYSMNP@PF127).
Fig. 2. (a) High resolution transmission electron microscopy (HR-TEM) bright field images of GYSMNP@PF127 with detail of the magnetite covered by few layers of
the graphene-based material; (b) DLS measurements with average hydrodynamic diameter (DH).
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(D, G and 2D) should be analysed regarding their intensities, shapes,
widths, positions and inter-correlations [45]. The G band corresponds
to an E2g mode of hexagonal graphite and the vibration of sp2-hy-
bridized carbon domain, while the D and 2D peaks are assigned to
structural defects [11,13]. The integrated peak intensity between ID and
IG was found to be 1.61, corresponding to a disordered graphene oxide
structure [44,46]. Moreover, by the deconvolution of the conventional
G band – or the apparent G band (Gapp), the actual G band (1546 cm−1)
and the D′ (1594 cm−1) can be assigned. The presence of the D′ band
was ascribed by Kaniyoor and Ramaprabhu [47], as proof of the pre-
sence of a highly defective structure comprising few layers of wrinkled
graphene-based (FlwG) structures, similar to the shell nanostructure
found in the synthesized GYSMNP material (cf. Fig. 2(a)).
The magnetic hysteresis curves obtained for Fe3O4 and GYSMNP are
shown in Fig. 3(f). GYSMNP exhibits saturation magnetization (Ms) of
69.8 emu g−1magnetite, which is close to the Ms of the bare magnetite core,
77.7 emu g−1magnetite. The Ms for these graphene-based magnetic nano-
particles is much higher than that reported for other yolk-shell nano-
particles [2,11,13,23], possibly due to the presence of super-
paramagnetic magnetite clusters as magnetic core. More interesting, the
superparamagnetic-like behaviour of GYSMNP was accentuated, as re-
vealed by the low-field data (inset in Fig. 3(f)), with negligible sa-
turation remanence (Mr) and low coercivity (Hc), respectively
1.2 emu g−1magnetite and 3.5 Oe, mainly due to lower magnetic dipolar
interaction between the magnetite cores, as consequence of the gra-
phene-based shell shielding.
Additionally, the main textural properties of the as-synthesized
GYSMNP material were analysed (Table S1, ESI). The specific surface
area (SBET) of GYSMNP was found to be 156m2 g−1. This relatively high
value in comparison with uncoated magnetite, 56m2 g−1 (data not
shown), is ascribed to the presence of the graphene-based shell in
GYSMNP. Moreover, the Vmicro/Vtotal ratio of 0.041 reveals a meso-
porous structure for GYSMNP. These textural properties of GYSMNP are
favourable for the encapsulation, transport and release of guest mole-
cules, such as chemotherapeutic drugs.
3.2. DOX loading studies
Doxorubicin (DOX) is a cationic chemotherapeutic drug and one of
the most commonly used against cancer [48]. However, it presents le-
thal side effects on healthy cells too [49]. Targeted drug delivery can be
an effective method to overcome this issue by delivering the cargo
specifically into tumours after been triggered by its abnormal acidic
microenvironment. Thus, DOX was chosen to explore the drug delivery
properties of GYSMNP@PF127, that shows promising potential to carry
high payloads of cationic drugs due to its negative surface charge, op-
timal size range, large surface area, mesoporous nature and hollow
cavity. The drug loading efficiency and drug loading capability were
assessed by incubating DOX concentrations between 50 and
500 μgmL−1 with a fixed amount of nanoparticles (500 μgmL−1). The
loading data are shown in Table 2.
Impressively, the drug loading capacity of GYSMNP@PF127 in-
creases with the increase of the initial DOX concentration, reaching an
outstanding 910 μg DOXmg−1GYSMNP@PF127 when the initial DOX con-
centration is 500 μgmL−1, which represents a 91% of drug loading
efficiency (1:1 w/w). These drug loading results show the extraordinary
capability of GYSMNP@PF127 to load high contents of DOX on its high
surface area. This ability can be ascribed to the π-π stacking interac-
tions between the aromatic rings of DOX and the carbonaceous struc-
ture of graphene-based nanoshells [50], as well as to some surface
groups. The post-synthetic functionalization of GYSMNP allowed a high
negative surface charge (zeta potential values ca. - 37mV (Table 1))
with pHPZC around 2 (i.e., pH at which the surface charge is zero),
which also allows electrostatic interactions with positively charged
DOX (pKa= 8.3) at pH 7.4 [51]. Thus, besides the physical bonding
between DOX and the graphene-based nanoparticles, which is generally
through π-π stacking between the aromatic rings, the high DOX loading
on GYSMNP@PF127 is also a consequence of the electrostatic interac-
tions and the mesoporous structure of the graphene-based shell. Ad-
ditionally, the mesoporous structure on GYSMNP suggests that DOX can
be additionally loaded into the hollow space created by the yolk-shell
architecture of these nanocarriers, increasing its loading drug capacity.
3.3. Dual pH- and temperature-dependent drug release
It is well-known that tumour microenvironment presents a weak
acidic pH value, around 6.0–7.2, at the tumour tissue due to the
Warburg effect, which dramatically decrease to severe acidic pH values,
around 4.5–5.5, in tumour endosome/lysosome environment [14]. The
pH differences between the tumour microenvironment and normal
tissues, with pH around 7.4, motivate the development of pH-depen-
dent/responsive nanocarriers that can be specifically designed as smart
drug delivery systems triggered by acidic pH values. Therefore, the
cumulative pH-dependent DOX release of GYSMNP@PF127-DOX was
studied under different pH conditions (7.4, 6.0 and 4.5, corresponding
to the mimicked physiological pH, tumour microenvironment and in-
tracellular tumour endosome/lysosome pH conditions, respectively)
either at 37 °C (physiological temperature) or 45 °C (hyperthermia
temperature), cf. Fig. 4.
Fig. 4 reveals that GYSMNP@PF127 has a pronounced pH- and
temperature-dependent drug delivery behaviour. The drug release at
these conditions takes place in two stages: (I) a rapid DOX release in the
first 8 h, followed by (II) a slower rate release till 48 h. Analysis of stage
(I) shows that just a very low amount of DOX was released at physio-
logical pH conditions (i.e. pH 7.4), both at 37 and 45 °C. The drug re-
lease was slightly higher at pH 6.0 than at pH 7.4, i.e., 20% versus 12%
at 37 °C, and 31% versus 18% at 45 °C. But remarkably, at pH 4.5, the
drug nanocarriers show an increase of the released DOX around 47% at
37 °C, and an impressive 76% at 45 °C. For the long-period drug release,
stage (II), just a maximum of 20% of DOX was released under physio-
logical conditions. Under pH 6.0, a maximum drug release of 25% and
36% was achieved for 37 and 45 °C, respectively, whereas at pH 4.5 a
remarkable 91% of the encapsulated drug was released at 45 °C. Once
again, the main reasons behind this promising pH/temperature-re-
sponsive drug release behaviour of the graphene-based material comes
from the π-π stacking between the graphene-based nanostructures and
the aromatic DOX molecules, which can be easily disrupted under a
mild acidic environment [13], but also due to the increased solubility of
DOX caused by the protonation process [11]. In this particular example,
this pH-dependent controlled release phenomenon can be also ascribed
Table 1
Colloidal, dimensional and magnetic properties of GYSMNP@PF127: void thickness, hydrodynamic diameter (DH), polydispersion (PDI), zeta potential and sa-
turation magnetization (Ms).






GYSMNP@PF127 0.7 ± 0.3 3.6 ± 1.3 180.0 ± 25.4 0.14 ± 0.02 - 36.8 ± 2.0 69.8
a Estimated by using ImageJ software from HR-STEM images as mean ± standard deviation (n= 60).
b Estimated by DLS and zeta potential measurements, in deionized water at 0.1 mgmL−1, represented as mean ± standard deviation (n= 3).
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to the increased protonation of the GYSMNP@PF127 nanocarrier sur-
face as the pH of the aqueous solution decreases from 7.4 to 4.5, with
the associated loss of negative surface charge. This will lead to a re-
duction of the electrostatic attraction between GYSMNP@PF127 and
DOX protonated molecules, increasing the progressive drug release.
Based on our characterizations and findings, pH has a much more
direct effect on the release of DOX than temperature (cf. Fig. 4), since at
pH 7.4 the released DOX is almost the same at 37 or 45 °C. This dif-
ference starts to be higher with decreasing pH values. Thus, as pH be-
comes more acidic, the temperature seems to have a more synergetic
effect. Our explanation is based on the fact that PF127 is considered a
thermosensitive polymer. This is because the hydrophobicity of the PPO
Fig. 3. Physicochemical and magnetic characterization of the GYSMNP materials. (a) Wide angle powder X-ray diffraction (XRD) patterns of Fe3O4 nanoparticles and
GYSMNP; (b) Thermogravimetric analysis of as-synthesized GYSMNP under air atmosphere; (c) FTIR spectra of (i) as-synthesized GYSMNP, (ii) GYSMNP after
activation with nitric acid, (iii) GYSMNP after functionalization with pluronic F-127 (GYSMNP@PF127); (d) Thermogravimetric analysis of the as-synthesized and
functionalized GYSMNP materials under N2 atmosphere; (e) Raman spectrum of as-synthesized GYSMNP with inset corresponding to the deconvolution of the
observed D and apparent G (Gapp) bands into actual G and D; (f) Magnetization curves of a) Fe3O4, b) GYSMNP. Hysteresis loops at room temperature, up
to± 20 kOe; the inset is a zoom for the low field region.
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block in Pluronic F127 changes as the temperature increases [52,53]. In
our particular case, this could lead to the increase of electrostatic re-
pulsion between PF127 and the nanosystem as the pH decreases, which
in turn can lead to a higher release of DOX to the medium when acid pH
and mild temperatures are combined. Overall, the pH/T-responsive
drug release results obtained in this work, suggest the great ability of
the designed graphene-based magnetic nanocarriers to be applied as
efficient drug encapsulation and delivery systems, with an especial
good pH/T sensitivity for an intelligent and on-demand drug release on
acidic tumour microenvironments.
3.4. Drug release kinetics
The results of the kinetic modelling, performed with the drug re-
lease data obtained for GYSMNP@PF127 (at 37 and 45 °C and different
pHs), are listed in Table 3. In this study, the drug release data obtained
for each pH and temperature tested condition were fitted to three ki-
netic models, namely first-order, Higuchi and Korsmeyer-Peppas. The
model with the higher R2 values (for each condition) was considered as
the best model.
The first-order and Higuchi kinetic models have very low R2 values
(slightly higher for the Higuchi model). These results suggest that the
drug release, under the tested conditions, is not mainly concentration-
dependent or total controlled by diffusion behaviour. The kinetic model
that fits better (higher R2) is the Korsmeyer-Peppas model, as expected
since it considers two parameters instead of one. The n values calcu-
lated from the Korsmeyer-Peppas model equation were found to be
lower than 0.45, suggesting that the drug release is essentially con-
trolled by simple quasi-Fickian diffusion mechanism.
3.5. Validation of GYSMNP@PF127-DOX as dual pH- and AMF/
temperature-responsive drug nanocarrier
The observed pH- and temperature-dependence drug delivery pro-
files highlight the convenience of exploiting the magnetic properties of
the magnetite cores to induce a temperature increase by external ap-
plication of an AMF (AC magnetic field). Thus, in addition to an en-
dogenous stimuli (pH) that boosts the localized drug release on the
tumour site, we can externally enhance this effect by inducing a tem-
perature increase through magnetic hyperthermia.
The response of GYSMNP@PF127-DOX as dual pH- and tempera-
ture-sensitive drug release nanocarrier was assessed under AMF
(f=340 kHz and H=21.0 kAm−1) during 30min. For this purpose,
3.0 mgmL−1 of GYSMNP@PF127-DOX, which corresponds to
1.6 mgmL−1 of unloaded-DOX GYSMNP@PF127, was dispersed in
phosphate buffer at pH 7.4 and 4.5. Mild hyperthermia temperature
(40–43 °C) was reached between 10 and 13min and maintained till the
end of the hyperthermia experiment (30min) (Fig. 5). From the initial
slope of the heating curve, SAR (specific absorption rate) and IPL (in-
trinsic power loss) values were estimated to be 334 and 402Wg Fe−1,
which correspond to 2.2 and 2.7 nHm2 kg−1, from samples dispersed in
phosphate buffer 7.4 and 4.5, respectively. These results represent a
much better heating efficiency than other magnetic nanomaterials
synthesized for hyperthermia application [12,15,54], and are in
agreement with IPL values (0.15–3.1 nHm2 kg−1) of commercial fer-
rofluids [15,55]. Moreover, these SAR and IPL values are similar to
those obtained for the unloaded-DOX GYSMNP@PF127 (Fig. S2, ESI),
showing that the loading of the drug does not significantly change the
Table 2
Drug loading on GYSMNP@PF127 at different initial DOX concentrations (50–500 μgmL−1) in phosphate buffer pH 7.4. Standard deviation of triplicate drug loading
tests (n=3).
Initial DOX concentration (μgmL−1)
50 100 200 300 400 500
Drug capacity (μgmg−1) 96.0 ± 1.0 196.5 ± 0.4 394.1 ± 1.0 587.0 ± 0.5 771.2 ± 9.0 910.5 ± 11.0
Drug efficiency (%) 96.0% 98.3% 98.5% 97.8% 96.4% 91.1%
Fig. 4. pH and thermo-responsive release of doxorubicin (DOX) from drug loaded GYSMNP@PF127 under different pH values (7.4, 6.0 and 4.5) and temperatures
(37 and 45 °C). Standard deviation of triplicate drug release tests (n=3).
Table 3
Drug release kinetic analysis of GYSMNP@PF127-DOX.
Temperature pH First-order Higuchi Korsmeyer-Peppas
K1 R2 Hh R2 Kkp n R2
37 °C 7.4 0.001 0.556 1.456 0.743 0.009 0.20 0.932
6.0 0.002 0.655 2.781 0.816 0.013 0.23 0.948
4.5 0.005 0.734 6.074 0.827 0.033 0.22 0.962
45 °C 7.4 0.001 0.575 1.346 0.758 0.016 0.13 0.977
6.0 0.002 0.638 2.608 0.797 0.027 0.14 0.980
4.5 0.014 0.849 6.676 0.818 0.066 0.14 0.984
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original heating performance.
After each drug release experiment under AMF, samples were cen-
trifuged and the supernatants (cf. insets of Fig. 5(a) and (b)), analysed
to determine the amount of DOX released. The results revealed that
after 30 min under AMF, just 6.8% of DOX is released at pH 7.4, while
45.6% at pH 4.5. The percentage of DOX released under AMF at pH 4.5,
is in the range of that obtained under external heating conditions at
45 °C in the first 30min, i.e., 44.0% (Fig. 4). Even though, under AMF
conditions, the temperature reached was slightly lower (40–43 °C) and
the length of the test was shorter (17min). These better drug release
performances observed in AMF can be ascribed to the local heating
effects in the vicinity of magnetic nanoparticles, which leads to an in-
crease of the temperature on their surface, without bringing a sig-
nificant increase in the surrounding medium [15]. Therefore, these
results suggest that under an AMF, the local heat generated on the
GYSMNP@PF127 surface can help the selective diffusion of loaded DOX
into the acidic tumour microenvironment through magnetic hy-
perthermia. Based on these results, the developed GYSMNP@PF127
material show high promise to act as dual endogenous pH- and exo-
genous AMF/temperature-responsive drug nanocarrier for controlled
drug delivery.
Table 4 shows the comparison of the GYSMNP@PF127 performance
with other reported carbon-based nanomaterials reported in literature
as magnetic drug delivery systems.
Overall, the developed GYSMNP@PF127 reported in this study ex-
hibits better combined parameters to be applied as efficient nanosystem
for the combined treatment of cancer than other carbon-based nano-
carriers (Table 4), namely: (i) excellent loading capacity, (ii) high pH-
sensitivity, (iii) highest total drug release at acidic pH, (iv) highest
magnetic saturation, and (v) superparamagnetic behaviour.
3.6. In vitro cell tests
3.6.1. Haemocompatibility assays
The haemocompatibility of GYSMNP@PF127 was evaluated by
haemolysis analysis, ranging the nanocarrier concentration between 10
and 500 μgmL−1 in diluted RBCs (red blood cells) during 3 h at 37 °C.
GYSMNP@PF127 shows a very low dose-dependent haemolytic activity
even at a very high concentrations (500 μgmL−1) with<4% of hae-
molysis, as inferred by the colourless supernatant obtained after 3 h of
incubation at 37 °C (Fig. S3, ESI). According to the standard ISO
10993–4 that evaluates biological medical devices suitable for blood
contact, GYSMNP@PF127 is suitable to be applied directly into the
blood stream by exhibiting haemolytic percentages lower than 5%
[22,61]. The colloidal stability of the nanocarriers dispersed in the
blood fluid for this experiment is shown in Fig. S4, ESI.
3.6.2. Cell cytotoxicity assays and cellular uptake of drug nanocarriers
The cell biocompatibility of GYSMNP@PF127 and cytotoxicological
effect of GYSMNP@PF127-DOX were investigated by SRB colorimetric
assay, where the growth inhibition of several concentrations of the
nanocarriers (0.05–50 μgmL−1) were assessed, Fig. 6. GYSMNP@
PF127 shows a good biocompatibility behaviour on healthy liver cells
PLP2, even after a long exposition time (48 h) with a GI50 of
58.86 ± 0.69 μgmL−1. To assess GYSMNP@PF127-DOX as drug re-
lease nanocarrier, research was carried out in tumour liver cell line,
HepG2. Fig. 6(b) illustrates a significant drop in the viability of the
tumour cells that can be attributed to the increasing concentration of
GYSMNP@PF127-DOX, showing a much lower GI50 of
7.34 ± 3.39 μgmL−1 when compared to GYSMNP@PF127. This result
suggests that just 7.34 μgmL−1 of the loaded nanocarrier system is
needed to induce 50% of reduction of tumour cells. At this concentra-
tion, no toxicological effect was observed in healthy cells. This higher
cytotoxicity observed for GYSMNP@PF127-DOX is attributed to the
DOX released on the tumour cells.
To a better understanding of the therapeutic effect of the DOX re-
leased by the GYSMNP@PF127 material over the tumour cells, HepG2
cells were incubated with the drug nanocarrier for 2, 4 and 6 h. In
addition, the cell nuclei were stained with Hoechst and microtubules
were immunolabeled with a monoclonal anti-α-tubulin antibody
(B512) combined with a secondary goat anti-mouse IgG antibody
conjugated with Alexa Fluor 488. Cells were observed using confocal
microscopy images obtained with Zeiss Laser Confocal Scanning
Microscope. Laser at 405 nm was used to observe the nucleus, 488 nm
to observe the microtubules and 561 nm to get the imaging from DOX
release. It can be observed (Fig. 7) that the red fluorescence intensity
from DOX increases along the incubation time between the nanocarriers
and the tumour cells. This observation reveals that the DOX is con-
tinuously released from GYSMNP@PF127-DOX nanocarriers. After 6 h,
the cell nuclei exhibit a strong DOX red fluorescence intensity, sug-
gesting that a high content of DOX is released into the cell cytoplasm
and reaches the nucleus after nanoparticle internationalization by en-
docytosis. The cellular uptake of drug nanocarriers is not only very
important for enhancing the drug delivery efficiency, but it is also
beneficial for magnetic hyperthermia therapy, allowing a combinatorial
thermo-chemotherapeutic effect.
Fig. 5. Magnetically induced thermal response curve of GYSMNP@PF127-DOX (3.0mg GYSMNP-DOX mL−1) for dual pH- and thermal-responsive drug delivery: (a)
dispersed in phosphate buffer at 7.4 to mimic physiological microenvironment, and (b) dispersed in phosphate buffer at 4.5 to mimic tumour microenvironment.
Samples were subjected to an AMF (f= 340 kHz and H=21.0 kAm−1) during 30min. Inset shows the drug-containing supernatant resulting from each hy-
perthermia experiment.
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This combined strategy represents an important step forward in the
fight against cancer and highlights this new generation of responsive
graphene-based nanocarriers as suitable therapeutic actuators on it.
Furthermore, their ability to be further functionalized with targeting
molecules opens new opportunities for the treatment of different tu-
mour types. Also, the presented magnetic nanocarriers might be opti-
mized with target molecules, for a more effective nanosystem for the in
vivo cancer therapy.
4. Conclusion
In this study, hydrophilic graphene-based yolk-shell magnetic
nanoparticles (GYSMNP) functionalized with copolymer PF-127, were
successfully developed as multifunctional nanocarriers for biomedical
applications. To enhance stability and biocompatibility of the gra-
phene-based nanomaterials, samples were chemically activated with
nitric acid and functionalized with copolymer PF-127. The results show
that this functionalization allowed the increment of the negative charge
of the nanocomposites from −17 to −37mV, which ascribes the in-
corporation of carboxylic acid groups and surface negative charge,
leading to the increase of their colloidal stability in aqueous solutions.
Moreover, this functionalization allowed the maintenance of colloidal
stability of GYSMNP@PF127 when using salty buffers (as phosphate
buffed saline) at different pH, as shown by the AMF hyperthermia
Fig. 6. Cell cytotoxicity assays investigated by SRB colorimetric assay after incubation of (a) GYSMNP@PF127 in healthy liver cell line PLP2; (b) GYSMNP@PF127-
DOX in tumour liver cell line HepG2, under different concentrations for 48 h.
Fig. 7. Confocal microscopy images of HepG2 cells incubated with GYSMNP@PF127-DOX at a concentration of 5 μgmL−1 during 2 h (a), 4 h (b) and 6 h (c). (i) Cell
nuclei stained with Hoechst and excited at 405 nm; (ii) DOX released in HepG2 cells and excited at 561 nm; (iii) Cell microtubules immunolabeled with the
monoclonal anti-tubulin antibody (B512) combined with a secondary goat anti-mouse IgG antibody conjugated with Alexa Fluor 488 excited at 488 nm; (iv) HepG2
cells using bright contrast; (v) Cell merge images.
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experiments, where the nanocarriers were able to continuously gen-
erate heat during 30min of the magnetic heating experiment. The same
colloidal stability was verified during the haemocompatibility experi-
ments, were sedimentation was not observed, even at the highest tested
concentration (Fig. S4, ESI). Impressively, this hybrid nanomaterial also
was found to be an efficient nanoheater at relatively low concentra-
tions, with exceptional drug loading capacity and controlled drug re-
lease triggered by the acidic tumour microenvironment. In addition, the
external application of an AMF (magnetic hyperthermia) was observed
to further induce a drug release, which was more significant at the
lowest pH tested. The dual pH- and temperature-responsive drug de-
livery behaviour observed in these nanosystems show a burst release of
the drug at mimicked acidic tumour environment, whereas at physio-
logical pH and temperature, negligible amount of drug is released,
confirming that the drug is efficiently retained in the nanocarrier.
Furthermore, the developed nanocarriers show good biocompatibility
after 48 h of nanoparticles-cells contact, excellent haemocompatibility
and nuclei drug internalization in a short period of time. More inter-
estingly, for future clinical applications, GYSMNP@PF127 can be easily
functionalized with other biomolecules in order to enhance its bio-
compatibility and tumour targeting (i.e., antibodies, aptamers, folic
acid, among others). The presented strategy and findings can represent
a new way to design and synthesize stable graphene-based materials
with novel structures for targeted combinatorial thermo-chemotherapy
triggered by abnormal acidic cell microenvironments on tumour site,
with the subsequent minimization of side effects on the healthy cells.
Acknowledgments
This work was financially supported by: Project POCI-01-0145-
FEDER-006984 – Associate Laboratory LSRE-LCM funded by FEDER
through COMPETE2020 - Programa Operacional Competitividade e
Internacionalização (POCI) – and by national funds through FCT -
Fundação para a Ciência e a Tecnologia, and by project NORTE-01-
0145-FEDER-029394, RTChip4Theranostics, supported by Programa
Operacional Regional do Norte - Norte Portugal Regional Operational
Programme (NORTE 2020), under the PORTUGAL 2020 Partnership
Agreement, through the European Regional Development Fund (ERDF)
and by Fundação para a Ciência e Tecnologia (FCT), IP. R.O.R. ac-
knowledges the Ph.D. scholarship SFRH/BD/97658/2013 granted by
FCT. A.M.T.S acknowledges the FCT Investigator 2013 Programme (IF/
01501/2013), with financing from the European Social Fund and the
Human Potential Operational Programme. G.D. acknowledges finan-
cing by Slovene Research Agency (J2-6754). M. B. acknowledges fi-
nancial funding from POCTEP (Co-operational Programme for Cross-
border Cooperation Spain-Portugal). This article is based upon work
from COST Action RADIOMAG (TD1402), supported by COST
(European Cooperation in Science and Technology).
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.msec.2018.07.060.
References
[1] B. Stewart, C.P. Wild, World Cancer Report 2014, International Agency for Research
on Cancer, Lyon, France, 2014.
[2] A.R.K. Sasikala, R.G. Thomas, A.R. Unnithan, B. Saravanakumar, Y.Y. Jeong,
C.H. Park, C.S. Kim, Sci. Rep. 6 (2016) 20543.
[3] X. Huang, S. Wu, X. Du, Carbon 101 (2016) 135–142.
[4] R. Tietze, J. Zaloga, H. Unterweger, S. Lyer, R.P. Friedrich, C. Janko, M. Pöttler,
S. Dürr, C. Alexiou, Biochem. Biophys. Res. Commun. 468 (2015) 463–470.
[5] Z. Li, E. Ye, David R. Lakshminarayanan, X.J. Loh, Small 12 (2016) 4782–4806.
[6] S. Mura, J. Nicolas, P. Couvreur, Nat. Mater. 12 (2013) 991–1003.
[7] C. Tao, Y. Zhu, Dalton Trans. 43 (2014) 15482–15490.
[8] Y. Xu, Y. Zhu, S. Kaskel, RSC Adv. 5 (2015) 99875–99883.
[9] Z. Tian, X. Yu, Z. Ruan, M. Zhu, Y. Zhu, N. Hanagata, Microporous Mesoporous
Mater. 256 (2018) 1–9.
[10] D. Chen, C.A. Dougherty, K. Zhu, H. Hong, J. Control. Release 210 (2015) 230–245.
[11] S. Li, J. Zheng, D. Chen, Y. Wu, W. Zhang, F. Zheng, J. Cao, H. Ma, Y. Liu, Nanoscale
5 (2013) 11718–11724.
[12] X. Yu, Y. Zhu, Sc. Tech. Adv. Mater. 17 (2016) 229–238.
[13] S. Mohapatra, S.R. Rout, R.K. Das, S. Nayak, S.K. Ghosh, Langmuir 32 (2016)
1611–1620.
[14] J. Liu, Z. Luo, J. Zhang, T. Luo, J. Zhou, X. Zhao, K. Cai, Biomaterials 83 (2016)
51–65.
[15] A. Hervault, A.E. Dunn, M. Lim, C. Boyer, D. Mott, S. Maenosono, N.T.K. Thanh,
Nanoscale 8 (2016) 12152–12161.
[16] S. Chandra, G. Noronha, S. Dietrich, H. Lang, D. Bahadur, J. Magn. Magn. Mater.
380 (2015) 7–12.
[17] Y. Wang, R. Zhao, S. Wang, Z. Liu, R. Tang, Biomaterials 75 (2016) 71–81.
[18] S. Li, J. Guo, R.A. Patel, A.L. Dadlani, R.M. Leblanc, Langmuir 29 (2013)
5742–5748.
[19] A. Pitto-Barry, N.P.E. Barry, Polym. Chem. 5 (2014) 3291–3297.
[20] Q. Zhou, Z. Zhang, T. Chen, X. Guo, S. Zhou, Colloids Surf. B 86 (2011) 45–57.
[21] A. Meshkini, H. Oveisi, Colloids Surf. B 158 (2017) 319–330.
[22] R.O. Rodrigues, M. Bañobre-López, J. Gallo, P.B. Tavares, A.M.T. Silva, R. Lima,
H.T. Gomes, J. Nanopart. Res. 18 (2016) 1–17.
[23] W.-J. Liu, Y.-X. Liu, X.-Y. Yan, G.-P. Yong, Y.-P. Xu, S.-M. Liu, J. Mater, Chem. A 2
(2014) 9600–9606.
[24] G.M. Mutlu, G.R.S. Budinger, A.A. Green, D. Urich, S. Soberanes, S.E. Chiarella,
G.F. Alheid, D.R. McCrimmon, I. Szleifer, M.C. Hersam, Nano Lett. 10 (2010)
1664–1670.
[25] S. Brunauer, P.H. Emmett, E. Teller, J. Am. Chem. Soc. 60 (1938) 309–319.
[26] F. Rodríguez-Reinoso, A. Linares-Solano, Chemestry and Physics of Carbon, Marcel
Dekker Inc., New York, 1989.
[27] R.S. Ribeiro, Z. Frontistis, D. Mantzavinos, D. Venieri, M. Antonopoulou,
I. Konstantinou, A.M.T. Silva, J.L. Faria, H.T. Gomes, Appl. Catal. B 199 (2016)
170–186.
[28] J. Siepmann, F. Siepmann, Int. J. Pharm. 364 (2008) 328–343.
[29] M. Szekeres, E. Illés, C. Janko, K. Farkas, I.Y. Tóth, D. Nesztor, I. Zupkó, I. Foldesi,
C. Alexiou, E. Tombácz, J. Nanomed. Nanotechnol. 6 (2015) 1000252.
[30] Y.V. Kolen'ko, M. Bañobre-López, C. Rodríguez-Abreu, E. Carbó-Argibay,
A. Sailsman, Y. Piñeiro-Redondo, M.F. Cerqueira, D.Y. Petrovykh, K. Kovnir,
O.I. Lebedev, J. Rivas, J. Phys. Chem. C 118 (2014) 8691–8701.
[31] X. Zhang, Y. Wang, Y. Zhao, L. Sun, Mater. Sci. Eng. C 77 (2017) 19–26.
[32] R.M.V. Abreu, I.C.F.R. Ferreira, R.C. Calhelha, R.T. Lima, M.H. Vasconcelos,
F. Adega, R. Chaves, M.-J.R.P. Queiroz, Eur. J. Med. Chem. 46 (2011) 5800–5806.
[33] B. Svobodova, L. Barros, R.C. Calhelha, S. Heleno, M.J. Alves, S. Walcott,
M. Bittova, V. Kuban, I.C.F.R. Ferreira, Ind. Crop. Prod. 95 (2017) 365–373.
[34] A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose,
J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo,
M. Boyd, J. Natl. Cancer Inst. 83 (1991) 757–766.
[35] W. Voigt, Sulforhodamine B Assay and Chemosensitivity, in: R.D. Blumenthal (Ed.),
Chemosensitivity: In Vitro Assays, Humana Press, Totowa, NJ, 2005, pp. 39–48.
[36] S.A.C. Lima, A. Gaspar, S. Reis, L. Durães, Mater. Sci. Eng. C 75 (2017) 1420–1426.
[37] L. Pradhan, R. Srivastava, D. Bahadur, Acta Biomater. 10 (2014) 2976–2987.
[38] G. Bharath, R. Madhu, S.-M. Chen, V. Veeramani, D. Mangalaraj, N. Ponpandian, J.
Mater. Chem. A 3 (2015) 15529–15539.
[39] L.M. Pastrana-Martínez, S. Morales-Torres, V. Likodimos, P. Falaras,
J.L. Figueiredo, J.L. Faria, A.M.T. Silva, Appl. Catal. B 158–159 (2014) 329–340.
[40] N. Kumar Sudesh, S. Das, C. Bernhard, G.D. Varma, Supercond. Sci. Technol. 26
(2013) 095008.
[41] X. Yang, Y. Wang, X. Huang, Y. Ma, Y. Huang, R. Yang, H. Duan, Y. Chen, J. Mater.
Chem. 21 (2011) 3448–3454.
[42] J.L. Figueiredo, J. Mater. Chem. A 1 (2013) 9351–9364.
[43] Q. Dou, A. Abdul Karim, X. Loh, Polym. J. 8 (2016) 341.
[44] A.C. Ferrari, J.C. Meyer, V. Scardaci, C. Casiraghi, M. Lazzeri, F. Mauri, S. Piscanec,
D. Jiang, K.S. Novoselov, S. Roth, A.K. Geim, Phys. Rev. Lett. 97 (2006) 187401.
[45] A.C. Ferrari, D.M. Basko, Nat. Nanotechnol. 8 (2013) 235–246.
[46] A.C. Ferrari, J. Robertson, Phys. Rev. B 61 (2000) 14095–14107.
[47] A. Kaniyoor, S. Ramaprabhu, AIP Adv. 2 (2012) 032183.
[48] P. Mohan, N. Rapoport, Mol. Pharm. 7 (2010) 1959–1973.
[49] M. Mahdavi, F. Rahmani, S. Nouranian, J. Mater. Chem. B 4 (2016) 7441–7451.
[50] M. Gisbert-Garzarán, M. Manzano, M. Vallet-Regí, Bioengineering 4 (2017) 1–27.
[51] A. Adnan, R. Lam, H. Chen, J. Lee, D.J. Schaffer, A.S. Barnard, G.C. Schatz, D. Ho,
W.K. Liu, Mol. Pharm. 8 (2011) 368–374.
[52] M.S.H. Akash, K. Rehman, S. Chen, Polym. Rev. 54 (2014) 573–597.
[53] W. Rao, W. Zhang, I. Poventud-Fuentes, Y. Wang, Y. Lei, P. Agarwal, B. Weekes,
C. Li, X. Lu, J. Yu, X. He, Acta Biomater. 10 (2014) 831–842.
[54] Y. Oh, M.S. Mooethy, P. Manivasagan, S. Bharathiraja, J. Oh, Biochimie 133 (2017)
7–19.
[55] P. Presa, Y. Luengo, M. Multigner, R. Costo, M.P. Morales, G. Rivero, A. Hernando,
J. Phys. Chem. C 116 (2012) 25602–25610.
[56] J. Wu, Y.S. Wang, X.Y. Yang, Y.Y. Liu, J.R. Yang, R. Yang, N. Zhang,
Nanotechnology 23 (2012) 355101.
[57] Z. Wang, C. Zhou, J. Xia, B. Via, Y. Xia, F. Zhang, Y. Li, L. Xia, Colloids Surf. B 106
(2013) 60–65.
[58] X. Tu, L. Wang, Y. Cao, Y. Ma, H. Shen, M. Zhang, Z. Zhang, Carbon 97 (2016)
35–44.
[59] M. Aliabadi, H. Shagholani, A. Yunessnia lehi, Int. J. Biol. Macromol. 98 (2017)
287–291.
[60] Y.-S. Huang, Y.-J. Lu, J.-P. Chen, J. Magn. Magn. Mater. 427 (2017) 34–40.
[61] Q. Wang, M. Shen, T. Zhao, Y. Xu, J. Lin, Y. Duan, H. Gu, Sci. Rep. 5 (2015) 7774.
R.O. Rodrigues et al. Materials Science & Engineering C 93 (2018) 206–217
217
